S&P 500
7,420.40
-0.15%
Dow Jones
51,990.40
-0.27%
Nasdaq 100
29,812.70
-0.18%
Russell 2000
2,996.17
-0.27%
FTSE 100
10,446.00
-0.29%
Nikkei 225
72,223.80
+1.55%

Investing

DBVT logo DBV Technologies : DBVT

DBVT

Stock Data

$15.60

Change down

$0.51 (3.17%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

DBV Technologies SA (DBVT) is a pioneering biopharmaceutical company headquartered in Montrouge, France, focused on revolutionizing food allergy treatment through its proprietary Viaskin™ technology platform. As a clinical-stage organization, DBV is dedicated to developing non-invasive epicutaneous immunotherapies aimed at promoting allergen desensitization, with a primary focus on peanut allergies. The company is currently advancing a robust pipeline through a series of clinical trials, positioning itself as a leader in addressing significant unmet medical needs in allergy management while striving to improve patient quality of life.

All DBV Technologies Articles

2 Articles